US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
This article was originally published in Scrip
The results of rigorous testing often can end in disappointment, despite the best hopes of drug makers, investigators and patients, as was the case for Genentech's Avastin (bevacizumab) in trying to prove itself as an effective and safe treatment for HER2-negative metastatic breast cancer (MBC), FDA Commissioner Margaret Hamburg said, in explaining her decision to rescind the drug's marketing approval for that use (scripintelligence, 18 November 2011).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.